西南医科大学学报2024，Vol.47Issue(2)：98-103,6.DOI:10.3969/j.issn.2096-3351.2024.02.002
CAR-T细胞免疫疗法在实体瘤中的研究进展
Research progress of CAR-T cell immunotherapy in solid tumors
摘要
Abstract
Chimeric antigen receptor T cell(CAR-T)therapy has achieved remarkable successes in treating refractory leuke-mia and other hematologic malignancies in the past ten years.At present,the FDA has approved six CAR-T cell products for hemato-logic malignancies including leukemia,lymphoma,etc.,highlighting the arrival of the era of immunotherapy and cell therapy for cancer.A large number of studies have indicated the potential of CAR-T cells in solid tumors.However,data from clinical trials was far from satisfactory yet.Obstacles interfering with the therapeutic effects of CAR-T cell therapy in solid tumors have been identified,including lack of reliable tumor-associated antigens,physical barriers within tumors,metabolic stress,immunosuppressive tumor environments,etc.Efforts should be made to further investigate the underlying mechanisms,and gene engineering technologies holds great potential for generation of more effective CAR-T strategies.This review aimed to provide a landscape view of recent progress for CAR-T cell therapy in solid tumors and discussed the challenges and future directions of CAR-T cell therapy.关键词
嵌合抗原受体T细胞/免疫治疗/实体瘤Key words
Chimeric antigen receptor T cell/Immunotherapy/Solid tumor分类
医药卫生引用本文复制引用
张淑群,马兴聪,孙诗雨,冯聪,贾艺玮..CAR-T细胞免疫疗法在实体瘤中的研究进展[J].西南医科大学学报,2024,47(2):98-103,6.基金项目
国家自然科学基金青年项目(82003047) （82003047）
吴阶平医学基金会(320.6750.2022-19-79) （320.6750.2022-19-79）
陕西省中西医结合肿瘤防治重点实验室建设项目(2022-ZXY-SYS-002) （2022-ZXY-SYS-002）
